GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE337nnn/GSE337046/primaryOK200TranscriptomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337046GEOGSEfalseThe distinct expression features between chronic phase and B-lymphoblastic crisis samples from patients with CMLChronic myeloid leukemia (CML) is a biphasic clonal hematopoietic stem cell disorder driven by the Philadelphia chromosome (Ph)-encoded BCR::ABL1 oncogene. The blast phase (BP) in CML progressed from indolent chronic phase (CP), usually has a dismal outcome. Single-cell RNA sequencing (scRNA-seq) have identified the pretreatment features linked to therapy resistance and disease progression. We performed the scRNA-seq on bone marrow cells derived from paired CML-CP and CML-BLBC samples, and found that CD24 displayed a striking upregulation in CML-BLBC samples when compared with both the CML-CP and Ph+ B-ALL samples, suggesting the potential as a target in the future therapy of patients with CML-BLBC. Therefore, we profiled the BM samples from patients with CML-CP (n = 16), CML-BLBC (n = 8), and de novo Ph+ B-ALL (n = 13) using bulk RNA sequencing to validate the upregulated expressio of CD24 in patients with CML-BLBC.2026/06/30GSE337046GSM9847389GSM9847401GSM9847388GSM9847402GSM9847400GSM9847405GSM9847406GSM9847403GSM9847404GSM9847409GSM9847407GSM9847408GSM9847381GSM9847383GSM9847382GSM9847385GSM9847384GSM9847387GSM9847386GSM9847412GSM9847399GSM9847413GSM9847410GSM9847411GSM9847416GSM9847417GSM9847414GSM9847415GSM9847390GSM9847392GSM9847391GSM9847394GSM9847393GSM9847396GSM9847395GSM9847398GSM984739724676337046Homo sapiens